Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (12): 1131-1137.doi: 10.35541/cjd.20220919
• Original Articles • Previous Articles Next Articles
Zhang Ying1, Zhang Chunlei1, Wang Wenhui1, Zhang Hua2, Wang Xiaoyu1, Zhou Xin1, Guo Jinzhu1
Received:
2022-12-27
Revised:
2023-08-26
Online:
2023-12-15
Published:
2023-12-05
Contact:
Guo Jinzhu
E-mail:guojinzhu_826@163.com
Supported by:
Zhang Ying, Zhang Chunlei, Wang Wenhui, Zhang Hua, Wang Xiaoyu, Zhou Xin, Guo Jinzhu. Comparative analysis of metabolic indicators in patients with persistent and non-persistent psoriasis[J]. Chinese Journal of Dermatology, 2023, 56(12): 1131-1137.doi:10.35541/cjd.20220919
[1] | Chen L, Shen Z. Tissue⁃resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders[J]. Cell Mol Immunol, 2020,17(1):64⁃75. doi: 10.1038/ s41423⁃019⁃0291⁃4. |
[2] | Masson Regnault M, Shourick J, Jendoubi F, et al. Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review[J]. Am J Clin Dermatol, 2022,23(4):433⁃447. doi: 10.1007/s40257⁃022⁃00679⁃y. |
[3] | Owczarek W, Dzik M, Narbutt J, et al. Real⁃world evidence on time to relapse of plaque psoriasis after discontinuation of biologic treatment in Poland[J]. Dermatol Ther, 2021,34(5):e15052. doi: 10.1111/dth.15052. |
[4] | Smith CH, Jabbar⁃Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017[J]. Br J Dermatol, 2017,177(3):628⁃636. doi: 10.1111/bjd.15665. |
[5] | Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update[J]. Br J Dermatol, 2020,183(4):628⁃637. doi: 10.1111/bjd.19039. |
[6] | Souza CS, de Castro C, Carneiro F, et al. Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: quality of life and prevalence[J]. J Dermatol, 2019,46(1):3⁃10. doi: 10.1111/1346⁃8138.14706. |
[7] | Pan Y, Tian T, Park CO, et al. Survival of tissue⁃resident memory T cells requires exogenous lipid uptake and metabolism[J]. Nature, 2017,543(7644):252⁃256. doi: 10.1038/nature21379. |
[8] | Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid⁃binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome[J]. Clin Chem, 2006,52(3):405⁃413. doi: 10.1373/clinchem.2005.062463. |
[9] | Yeung DC, Wang Y, Xu A, et al. Epidermal fatty⁃acid⁃binding protein: a new circulating biomarker associated with cardio⁃metabolic risk factors and carotid atherosclerosis[J]. Eur Heart J, 2008,29(17):2156⁃2163. doi: 10.1093/eurheartj/ehn295. |
[10] | Ibarretxe D, Girona J, Amigó N, et al. Impact of epidermal fatty acid binding protein on 2D⁃NMR⁃assessed atherogenic dyslipidemia and related disorders[J]. J Clin Lipidol, 2016,10(2):330⁃338.e2. doi: 10.1016/j.jacl.2015.12.012. |
[11] | Kralisch S, Fasshauer M. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?[J]. Diabetologia, 2013,56(1):10⁃21. doi: 10. 1007/s00125⁃012⁃2737⁃4. |
[12] | Tso AW, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10⁃year prospective study in a Chinese cohort[J]. Diabetes Care, 2007,30(10):2667⁃2672. doi: 10.2337/ dc07⁃0413. |
[13] | Xu A, Tso A W, Cheung B M, et al. Circulating adipocyte⁃fatty acid binding protein levels predict the development of the metabolic syndrome: a 5⁃year prospective study[J]. Circulation, 2007,115(12):1537⁃1543. doi: 10.1161/circulationaha.106.647503. |
[14] | Alotaibi HA. Effects of weight loss on psoriasis: a review of clinical trials[J]. Cureus, 2018,10(10):e3491. doi: 10.7759/cureus.3491. |
[15] | 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华心血管病杂志, 2016,44(10):833⁃853. doi: 10.3760/cma.j.issn.0253⁃3758.2016. 10.005. |
[16] | Duan MM, Ma YX, Zhang JZ, et al. Analysis of clinical features of patients with psoriasis and metabolic syndrome in Xinjiang[J/OL]. Int J Dermatol Venereol, 2023. doi: 10.1097/JD9.0000000 000000287. [published online ahead of print 2023⁃01⁃10]. |
[17] | Blauvelt A, Armstrong AW, Langley RG, et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate⁃to⁃severe plaque psoriasis: results from the ECLIPSE study[J]. J Dermatolog Treat, 2022,33(4):2317⁃2324. doi: 10.1080/09546634.2021.1959504. |
[18] | Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry[J]. J Am Acad Dermatol, 2022,86(1):68⁃76. doi: 10.1016/j.jaad.2021.06.883. |
[19] | Al⁃Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial[J]. Expert Opin Biol Ther, 2014,14(6):749⁃756. doi: 10.1517/14712598. 2014.900541. |
[20] | Warren RB, Carrascosa JM, Fumero E, et al. Time to relapse after tildrakizumab withdrawal in patients with moderate⁃to⁃severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial[J]. J Eur Acad Dermatol Venereol, 2021,35(4):919⁃927. doi: 10.1111/jdv.16964. |
[21] | Stinco G, Balato N, Buligan C, et al. A multicenter retrospective case⁃control study on Suspension of TNF⁃inhibitors and Outcomes in Psoriatic patients (STOP study)[J]. G Ital Dermatol Venereol, 2019,154(4):392⁃399. doi: 10.23736/S0392⁃0488.18.06156⁃4. |
[22] | Baran A, Świderska M, Bacharewicz⁃Szczerbicka J, et al. Serum fatty acid⁃binding protein 4 is increased in patients with psoriasis[J]. Lipids, 2017,52(1):51⁃60. doi: 10.1007/s11745⁃016⁃4211⁃4. |
[23] | Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs⁃⁃mechanisms and therapeutic implications[J]. Nat Rev Endocrinol, 2015,11(10):592⁃605. doi: 10.1038/nrendo.2015.122. |
[24] | Kozłowska D, Myśliwiec H, Harasim⁃Symbor E, et al. Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis[J]. Mol Biol Rep, 2021,48(5):4421⁃4429. doi: 10.1007/s11033⁃021⁃06461⁃3. |
[25] | Owczarczyk⁃Saczonek A, Czerwiñska J, Orylska M, et al. Effect of methotrexate treatment on the expression of epidermal⁃fatty acid⁃binding protein (E⁃FABP) and apolipoproteins in patients with psoriasis[J]. Postepy Dermatol Alergol, 2020,37(3):401⁃406. doi: 10.5114/ada.2020.96109. |
[26] | Yilmaz E, Tamer E, Artüz F, et al. Evaluation of serum uric acid levels in psoriasis vulgaris[J]. Turk J Med Sci, 2017,47(2):531⁃534. doi: 10.3906/sag⁃1512⁃5. |
[27] | Gui XY, Jin HZ, Wang ZJ, et al. Serum uric acid levels and hyperuricemia in patients with psoriasis: a hospital⁃based cross⁃sectional study[J]. An Bras Dermatol, 2018,93(5):761⁃763. doi: 10.1590/abd1806⁃4841.20187547. |
[28] | Elmets CA, Leonardi CL, Davis D, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities[J]. J Am Acad Dermatol, 2019,80(4):1073⁃1113. doi: 10.1016/j.jaad.2018.11. 058. |
[29] | Yanai H, Adachi H, Hakoshima M, et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease[J]. Int J Mol Sci, 2021, 22(17): 9221. doi: 10.3390/ijms22179221. |
[30] | Chi CC, Wang J, Chen YF, et al. Risk of incident chronic kidney disease and end⁃stage renal disease in patients with psoriasis: a nationwide population⁃based cohort study[J]. J Dermatol Sci, 2015,78(3):232⁃238. doi: 10.1016/j.jdermsci.2015.03.012. |
[31] | Chiu HY, Hui RC, Tsai TF, et al. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8⁃year multicenter study[J]. J Am Acad Dermatol, 2023,88(1):71⁃78. doi: 10.1016/j.jaad.2019.01. 035. |
[32] | Beygi S, Lajevardi V, Abedini R. C⁃reactive protein in psoriasis: a review of the literature[J]. J Eur Acad Dermatol Venereol, 2014,28(6):700⁃711. doi: 10.1111/jdv.12257. |
[33] | Hagino T, Saeki H, Kanda N. Biomarkers and predictive factors for treatment response to tumor necrosis factor⁃α inhibitors in patients with psoriasis[J]. J Clin Med, 2023,12(3):974. doi:10.3390/jcm12030974. |
[1] | Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881. |
[2] | Ye Hui, Deng Shilin, Liang Jingyao, Zhang Xibao. Correlations between the control of atopic dermatitis recurrence and tissue-resident memory T cells [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240192-e20240192. |
[3] | Wang Wenqiu, Li Chengxin, Wang Rui. Biologics for the treatment of psoriasis relapse: current status [J]. Chinese Journal of Dermatology, 2025, 0(3): 20230301-e20230301. |
[4] | Li Xiuzhen, Xu Xiulian. Effects of interleukin-23 inhibitors on psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2025, 58(3): 268-272. |
[5] | Lianghong Chen Yan SUN Jing-Yu WANG. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2025, 58(3): 266-268. |
[6] | Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis [J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88. |
[7] | Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52. |
[8] | Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75. |
[9] | Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829. |
[10] | Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769. |
[11] | Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 57(8): 743-746. |
[12] | Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742. |
[13] | Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2024, 57(6): 570-574. |
[14] | Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444. |
[15] | China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417. |
|